Corindus Vascular Robotics to host breakfast symposium featuring the CorPath System “Robotic PCI: Precision and Protection from Occupational Hazards”
Waltham, MA – September 3, 2014 – Precision and radiation protection benefits afforded by robotic - assisted technology will be the focus of a symposium sponsored by Corindus Vascular Robotics at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting. “Robotic PCI: Precision and Protection from Occupational Hazards” will highlight presentations from renowned interventional cardiologists on the advantages offered by robotic - assisted percutaneous coronary intervention (PCI) procedures on Tuesday, Sept. 16 at 6:30 a.m. EDT at the Walter E. Washington Convention Center, Room 144A, Washington, D.C.
The symposium will be chaired by Ehtisham Mahmud, M.D., Director, Sulpizio Cardiovascular Center - Medicine, UC San Diego, and Giora Weisz, M.D., Chairman of Cardiology, Shaare Zedek Medical Center. An audience discussion and Q&A will follow the presentation.
“Robotic assistance in coronary stenting continues to expand with the ability to treat more complex cases. We are able to take advantage of the robotic precision in guidewire manipulation and the improved visualization in the cockpit.” said Dr. Mahmud. “The actual process for doing a PCI has remained unchanged for many years, with the physician standing at the bedside manually positioning devices. Now, with robotic - assisted PCI, we have a new tool that is changing the procedure and reducing radiation exposure to the operator while potentially improving the procedure for the patient.”
Interventional cardiologists experience the highest amounts of radiation exposure of any medical professionals, as shown in a publication by Venneri, et al. Exposure to radiation increases an Interventionalist’s risk of cancer and cataracts. A recent study published by Roguin, et al. found that 86% of Interventionalists who self-reported brain tumors had the malignancy on the left side, which is the side closest to the x-ray source during procedures. Exposure to radiation, as demonstrated by Vano, et al., has also led to 50% of Interventionalists displaying significant posterior subcapsular lens changes, a precursor to cataracts, which are typical of ionizing radiation exposure. The CorPath System’s interventional cockpit provides radiation-shielding that can protect the operator from radiation exposure during PCI cases.
“We are committed to protecting physicians in the cath lab,” said David Handler, President and CEO, Corindus Vascular Robotics. “This symposium will illustrate the impact robotic-assisted PCI can have on patient outcomes as well as the benefits of reducing occupational hazards such as radiation exposure and musculoskeletal disorders.”
“Robotic PCI: Precision and Protection from Occupational Hazards” will feature the following speakers and topics:
For more information and to register for the symposium, “Robotic PCI: Precision and Protection from Occupational Hazards,” click here.
To take advantage of an exclusive opportunity to use the CorPath System with a live simulator, register here and visit Corindus at booth #1342 at TCT 2014.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: